ReviewScars, burns & healing
TGF-β1 -509C/T polymorphism and susceptibility to keloid disease: a systematic review and meta-analysis.
Review in Scars, burns & healing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway.Scientific reports · 2025Article
- Update on the Pathogenesis of Keloid Formation.JID innovations : skin science from molecules to population health · 2024Review
- Scarring Skin: Mechanisms and Therapies.International journal of molecular sciences · 2024Review
- Outcomes of Surgical Excision and High-Dose-Rate Brachytherapy for Earlobe Keloids.World journal of plastic surgery · 2021Article
- Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.Molecular diagnosis & therapy · 2019Article
- TGF-β1 -509C/T polymorphism and susceptibility to keloid disease: a systematic review and meta-analysis.Scars, burns & healingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKeloid disease (KD) is common and often refractory to treatment. Definition of the genetic mechanisms of KD can lead to a better understanding of the disease and suggest more effective treatment strategies.
objectivesTo quantitatively estimate the association between KD susceptibility and the -509C/T polymorphism in the TGF-β1 gene.
methodsPubMed, Embase and CNKI databases were searched using a combination of the Medical Subject Headings (MeSH) and relevant words in titles. Analyses were performed with STATA 12.0.
resultsFive case-control studies encompassing a total of 564 keloid cases and 620 healthy controls were pooled in the final meta-analysis. Among the five studies, no significant association was detected between the TGF-β1 -509C/T polymorphism and KD under all of the five genetic models (allele comparison, heterozygote comparison, homozygote comparison, dominant model and recessive model) for the overall analyses and for the subgroup analyses based on DNA extraction method, participant ethnicity and group size. When stratified by study quality, three high-quality studies showed significant association under allele comparison and homozygote model (C versus T: OR = 0.80, 95% confidence interval [CI] = 0.65-0.98,
conclusionsThe current meta-analysis suggests that the TGF-β1 -509C/T polymorphism is not associated with KD susceptibility. High-quality and large-scale studies are needed to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.